Results 351 to 360 of about 1,881,376 (382)

Neutralizing Antibody Responses to Chlamydia trachomatis in Women and Associations With Chlamydia Outcomes. [PDF]

J Infect Dis
Yu H, Geisler WM, Dai C, Gupta K, Cutter G, Brunham RC.   +5 more
europepmc   +1 more source

Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody

Mahomed S, Mkhize NN, Serebryannyy LA, Hermanus T, Kgagudi P, Kaldine H, Lambson B, Narpala SR, Basappa M, Castro M, Lin BC, Carlton K, Sands JT, Gall JG, Koup RA, Morris L, Karim QA, Moore PL, Karim SA, Doria-Rose N.   +19 more
europepmc   +1 more source

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults. [PDF]

J Infect Dis
Samandari T, Achola M, Hutter JN, Mboya G, Otieno W, Kee JJ, Huang Y, Aponte JJ, Ockenhouse CF, Lee CK, Polakowski L, Yacovone M, Tapley A, Dadabhai S, Mkhize NN, Kaldine H, Bhebhe S, Moore PL, Hural J, Garrett N, Kublin JG.   +20 more
europepmc   +1 more source

Structure of ClfA002 in Complex With Neutralizing Antibody AZD7745 Provides Insight into Its Broad Neutralization Mechanism in Staphylococcus aureus Infection. [PDF]

J Infect Dis
Tkaczyk C, Keren-Kaplan T, Gamson A, Warrener P, Semenova E, Rosenthal K, Barnes A, Ahani B, Sellman BR, Podlaha O, Oganesyan V.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Broadly Neutralizing Antiviral Antibodies

Annual Review of Immunology, 2013
A fascinating aspect of viral evolution relates to the ability of viruses to escape the adaptive immune response. The widely held view has been that the great variability of viral glycoproteins would be an absolute obstacle to the development of antibody-based therapies or vaccines that could confer broad and long-lasting protection.
Corti D., Lanzavecchia A.
openaire   +2 more sources

Neutralizing Antibodies Against Calcitonin

Hormone and Metabolic Research, 1993
The use of calcitonin (CT) is established as a treatment of Paget's disease of bone and postmenopausal osteoporosis (PMO). Salmon calcitonin (sCT), which differs in 14 of the 32 amino acids from human calcitonin, has found a wider distribution world wide, although antibody formation against sCT has been reported in more than 70% of the patients on ...
A, Grauer, H H, Reinel, R, Ziegler, F, Raue   +3 more
openaire   +2 more sources

Production of Neutralizing Antibody

2018
Techniques employing monoclonal antibodies (mAbs) are widely used in the initial development phase of biologics. The usefulness of mAbs in basic RA research has been established based on their characteristics, including specificity of binding, homogeneity, and ability to be produced on a large scale.
Erika, Takemasa, Shuang, Liu, Hitoshi, Hasegawa   +2 more
openaire   +2 more sources

Antibody Neutralization in Hypoprothrombinaemic Plasma

Pathophysiology of Haemostasis and Thrombosis, 1972
The technique of antibody neutralization has been used to study the plasma of a large group of patients with hypoprothrombinaemia of diverse causes. The associated disorders included obstructive jaundice, acute infective hepatitis and chronic parenchymal liver disease. A number of patients were receiving warfarin and salicylate therapy. Irrespective of
J D, Parkin, F, Madaras, P A, Castaldi
openaire   +2 more sources

Neutralizing antibody in rodent malaria

Transactions of the Royal Society of Tropical Medicine and Hygiene, 1975
Small numbers of rat erythrocytes infected with viable P. berghei, when inoculated into susceptible rats together with hyperimmune rat serum (HIS), are fully neutralized. Serum from convalescent rats delays the onset of patency but does not neutralize. The neutralizing efficiency of HIS rises in proportion to the number of successive reinoculations of ...
J, Golenser, D T, Spira, A, Zuckerman
openaire   +2 more sources

Protective neutralizing antibodies

Science, 2020
Coronavirus Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al.
openaire   +1 more source